98%
921
2 minutes
20
Ischemic stroke is a worldwide disease with high mortality and morbidity. Kv7/KCNQ channels are key modulators of neuronal excitability and microglia function, and activation of Kv7/KCNQ channels has emerged as a potential therapeutic avenue for ischemic stroke. In the present study, we focused on a new Kv7/KCNQ channel opener QO-83 on the stroke outcomes and its therapeutic potential. Transient or distal middle cerebral artery occlusion model was established with C57 mouse to evaluate the role of QO-83. Solitary dose of QO-83 contributes to the microglia inhibition and fibrotic scar mitigation post stroke. QO83 shows prominent effect on reducing infarction area, alleviating cerebral edema, maintaining blood-brain barrier integrity, and enhancing neurogenesis. Single-nucleus RNA sequencing unveils neuroprotection and specific microglial subclusters influenced by QO-83. More importantly, QO83 shows promise in enhancing survival rates with dose dependence. Notably, these protective effects extend beyond the 4-6 h post-reperfusion window. Additionally, continuous dosing of QO-83 correlates with enhanced cognition. In conclusion, this study highlights QO-83 as a protective agent against ischemic brain injury, showcasing its multifaceted effects and potential as a therapeutic strategy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12975-025-01329-1 | DOI Listing |
Neurol Res
September 2025
Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USA.
Background: The benefits of rehabilitation in acute ischemic stroke patients following thrombectomy remain underexplored. We assessed which activities of daily living (ADLs) show the greatest improvement after goal-directed therapy in an inpatient rehabilitation setting.
Methods: We retrospectively analyzed pre- and post-rehabilitation functional assessments in 40 acute ischemic stroke patients treated with mechanical thrombectomy.
CNS Drugs
September 2025
Global Health Neurology Lab, Sydney, NSW, 2150, Australia.
Acute ischemic stroke (AIS) remains a leading cause of mortality and long-term disability globally, with survivors at high risk of recurrent stroke, cardiovascular events, and post-stroke dementia. Statins, while widely used for their lipid-lowering effects, also possess pleiotropic properties, including anti-inflammatory, endothelial-stabilizing, and neuroprotective actions, which may offer added benefit in AIS management. This article synthesizes emerging evidence on statins' dual mechanisms of action and evaluates their role in reducing recurrence, improving survival, and mitigating cognitive decline.
View Article and Find Full Text PDFClin Neuroradiol
September 2025
Department of Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Background: Pediatric acute ischemic stroke is a rare yet severe condition with multifactorial etiology, often associated with vasculopathies. Endovascular intervention in children with focal cerebral arteriopathy is seldom reported.
Purpose: Our aim was to report feasibility of intracranial rescue stenting for the management of pediatric focal cerebral arteriopathy with flow-limiting stenosis.
Neurol Res
September 2025
Department of Human Anatomy, Wannan Medical College, Wuhu, China.
Background: Ischemic stroke can damage the cerebral white matter, resulting in myelin loss and neurological deficits. Moreover, microglial activation plays an important role in ischemic stroke; therefore, inhibiting microglial activation has become an effective therapeutic target for ischemic stroke.
Objective: This study aimed to investigate the effects of electroacupuncture (EA) on microglial activation and polarization, and the role of oligodendrocyte genesis in myelin reformation after ischemic stroke.
Background: This study aimed to evaluate the predictive value of combining the Padua score with D-dimer levels for identifying lower extremity deep vein thrombosis (DVT) in acute ischemic stroke (AIS) patients undergoing intravenous thrombolysis with alteplase.
Methods: This retrospective study analyzed clinical data from 632 AIS patients who received alteplase treatment at our hospital between September 2019 and October 2023. After applying strict inclusion and exclusion criteria, a total of 172 patients were included in the analysis: 35 patients in the DVT group and 137 patients in the non-DVT group.